Evidence map›Paper›PMID 38686611›Full record

ArticleHistopathology2024

Multilineage involvement in KMT2A-rearranged B acute lymphoblastic leukaemia: cell-of-origin, biology, and clinical implications.

Umut Aypar, Deepika Dilip, Ramya Gadde, Dory M Londono, Ying Liu, Qi Gao, Mark B Geyer, Andriy Derkach, Yanming Zhang, Jacob L Glass and 2 more

Abstract read
In one paragraph

Article in Histopathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Umut AyparDepartment of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-2226-6163
Deepika DilipCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ramya GaddeDepartment of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dory M LondonoDepartment of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ying LiuDepartment of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID https://orcid.org/0000-0002-9167-3205
Qi GaoDepartment of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mark B GeyerDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andriy DerkachDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yanming ZhangDepartment of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jacob L GlassDepartment of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mikhail RoshalDepartment of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenbin XiaoDepartment of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Lineage identification and targeted therapeutics in acute leukemiaK08CA230172 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GLASS, JACOB LOWELL · 2019 to 2023
$1.4M
Assessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemiaK08CA267058 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI XIAO, WENBIN · 2022 to 2025
$1.1M
Alex's Lemonade Stand FoundationCycle for Survival's Equinox Innovation Award in Rare CancersEquinox Cycle for SurvivalMSK Department of Pathology Internal Research FundMSK Leukaemia SPORE Career Enhancement Program,NCI NIH HHS K08 CA230172NCI NIH HHS K08 CA267058NCI NIH HHS P30 CA008748Runx1 Research Program
6 · The paper itself

Abstract

aimsB lymphoblastic leukaemia/lymphoma (B-ALL) is thought to originate from Pro/Pre-B cells and the genetic aberrations largely reside in lymphoid-committed cells. A recent study demonstrated that a proportion of paediatric B-ALL patients have BCR::ABL1 fusion in myeloid cells, suggesting a chronic myeloid leukaemia (CML)-like biology in this peculiar subset of B-ALL, although it is not entirely clear if the CD19-negative precursor compartment is a source of the myeloid cells. Moreover, the observation has not yet been extended to other fusion-driven B-ALLs. METHODS AND

resultsIn this study we investigated a cohort of KMT2A-rearranged B-ALL patients with a comparison to BCR::ABL1-rearranged B-ALL by performing cell sorting via flow cytometry followed by FISH (fluorescence in situ hybridization) analysis on each of the sorted populations. In addition, RNA sequencing was performed on one of the sorted populations. These analyses showed that (1) multilineage involvement was present in 53% of BCR::ABL1 and 36% of KMT2A-rearranged B-ALL regardless of age, (2) multilineage involvement created pitfalls for residual disease monitoring, and (3) HSPC transcriptome signatures were upregulated in KMT2A-rearranged B-ALL with multilineage involvement.

conclusionsIn summary, multilineage involvement is common in both BCR::ABL1-rearranged and KMT2A-rearranged B-ALL, which should be taken into consideration when interpreting the disease burden during the clinical course.

Indexed as

Histone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinAdolescentAdultAgedChildChild, PreschoolFemaleFusion Proteins, bcr-ablGene RearrangementHumansInfantIn Situ Hybridization, FluorescenceMaleMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-LymphomaFusion Proteins, bcr-ablHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID38686611
PMCPMC11246803

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.